World Journal of
Pharmaceutical and Life Sciences

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Indian Science Publications, SOCOLAR, China, Cosmos Impact Factor, Research Bible, Fuchu, Tokyo. JAPAN, Scientific Indexing Services (SIS), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Scientific Indexing, UAE, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Indian citation Index (ICI), IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Directory of Research Journals Indexing, 



Saerah Simon*, Reza Rajesh, Roshni Acha Biju, Renuka R. and Elessy Abraham


Atopic Dermatitis (AD) is a highly pruritic chronic inflammatory skin disease that commonly presents during early childhood. It is a special form of eczematous dermatitis with wide range of severity. Several studies indicate that the disease is very common in western world with lifetime prevalence in children of 10% to 20%. In most patients it occurs before 5 yrs and typically clears by adolescence. AD has an immunologic basis. Both innate and adaptive immune responses are impaired in AD patients. Intense pruritis is a hallmark of the disease which leads to extensive scratching and further breakdown of the skin barrier. Treatment of atopic eczema should be based on a “stepped-care plan” where treatments are stepped up or down depending on the assessment of the state of the child’s skin by the physician. Both topical and systemic treatments are given for eczema. Topical corticosteroids and calcineurin inhibitors are used as topical anti-inflammatory agents. Patients should be carefully instructed about the use of topical glucocorticoids to avoid side effects. Newer drugs used in treatment of AD are Crisaborole ointment and Dupilumab injection. FDA approved these drugs on 14th December 2016 and 28th March 2017 respectively.

[Full Text Article]


World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here